A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension
Recruiting
N/A
Interventional Study
Artificial Intelligence (AI)
Artificial Intelligence (AI) in Diagnosis
Hypertension, Pulmonary
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 50 – 85
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 8,666 (estimated)
- Sponsor
- National Defense Medical Center, Taiwan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study aims to validate the use of an artificial intelligence-enabled electrocardiogram (AI-ECG) to screen for elevated PAP. We hypothesize that the AI-ECG model can early identify patients with pulmonary hypertension in high-risk patients, prompting further evaluation through echocardiography, potentially resulting in improving cardiovascular outcomes.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Men or women, ≥ 50 to 85 years of age
* At least one 12-lead ECG within 3 months
Exclusion Criteria:
* A diagnosis of PH WHO Groups 1, 2, 3, 4, or 5
* A diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or i…
Contacts